Copyright © 2000 by the European Society of Cardiology.
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure
a Cardiovascular Institute, Hospital Clinical, University of Barcelona, Barcelona, Spain
b Hormonal Laboratory, Hospital Clinical, University of Barcelona, Barcelona, Spain
revised June 7, 1999; accepted June 9, 1999
Abstract
Aims The aim of the study was to assess the incidence and clinical implications of increased plasma angiotensin II despite chronic ACE inhibitor therapy in patients with heart failure.
Methods and Results The studied population consisted of 70 patients (mean age 59±9 years). Plasma renin activity and plasma concentration of aldosterone, norepinephrine, atrial natriuretic peptide, angiotensin II, tumour necrosis factor, interleukin-6 and interleukin-1B were assessed at 6 months of ACE inhibitor therapy. Mean left ventricular ejection fraction was 24±5% and the end-systolic and end-diastolic diameters were 59±9 and 71±8mm, respectively. Despite chronic enalapril or captopril therapy, 35 patients (50%) had increased plasma angiotensin II (median 33pg.ml–1, range 17–84), while it was in the normal range in the remaining 35 patients (median 10pg.ml–1, range 5–15). Plasma renin activity (P=0·005), interleukin-6 (P=0·004), New York Heart Association functional class III-IV (P=0·006), furosemide dose (P=0·01), lack of beta-blocker therapy (P=0·04) and norepinephrine (P=0·04) were univariately associated with increased angiotensin II. Multivariate regression analysis identified the plasma renin activity (0·0004), norepinephrine (0·02) and interleukin-6 (0·03) as independent predictors of plasma angiotensin II. During follow-up (35±29 months), nine (12·8%) patients died and 13 had new heart failure episodes. Increased plasma angiotensin II, despite ACE inhibitor therapy, was a significant predictor of death or heart failure according to the Kaplan–Meier survival method by log rank test (P=0·002).
Conclusion Fifty per cent of patients with heart failure, had increased plasma angiotension II despite chronic ACE inhibitor therapy. These patients had higher neurohormonal activation and poor prognosis.
Key Words: Angiotensin II, ACE inhibitors, prognosis, heart failure
f1 Correspondence: Eulàlia Roig, MD, Cardiovascular Institute, Hospital Clinic, C/Villarroel 170, Barcelona 08036, Spain.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Jessup, B. M. Westwood, M. C. Chappell, and L. Groban Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 245 - 257. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Muller and D. N. Muller Battle against the renin-angiotensin system: help from an unexpected party Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1110 - 1112. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Westermann, A. Riad, O. Lettau, A. Roks, K. Savvatis, P. M. Becher, F. Escher, A.H. Jan Danser, H.-P. Schultheiss, and C. Tschope Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure Hypertension, December 1, 2008; 52(6): 1068 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, and Y. C. Li Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase PNAS, October 14, 2008; 105(41): 15896 - 15901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Li, L. Gao, I. H. Zucker, and H. D. Schultz NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits Cardiovasc Res, August 1, 2007; 75(3): 546 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Roig Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E12 - E17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Li and H. D. Schultz Enhanced sensitivity of Kv channels to hypoxia in the rabbit carotid body in heart failure: role of angiotensin II J. Physiol., August 15, 2006; 575(1): 215 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Li, X.-H. Xia, H. Zheng, L. Gao, Y.-F. Li, D. Liu, K. P. Patel, W. Wang, and H. D. Schultz Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits Cardiovasc Res, July 1, 2006; 71(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ponikowski Rationale and design of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C35 - C42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Nickenig, J. Ostergren, and H. Struijker-Boudier Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1_suppl): S1 - S7. [Abstract] [PDF]
|
|
|
|
|
|
P. P Liu, A. Maggioni, and E. J Velazquez Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1_suppl): S19 - S22. [Abstract] [PDF]
|
|
|
|
 |
|
 D. N. Muller and F. C. Luft Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
|
|
P. van der Harst, M. Volbeda, A. A. Voors, H. Buikema, S. Wassmann, M. Bohm, G. Nickenig, and W. H. van Gilst Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting Hypertension, December 1, 2004; 44(6): 930 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Gring and G. S. Francis A hard look at angiotensin receptor blockers in heart failure J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1841 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur. Heart J., October 1, 2003; 24(19): 1727 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jones, S. S. Dhamrait, J. R. Payne, E. Hawe, P. Li, I. S. Toor, L. Luong, P. T.E. Wootton, G. J. Miller, S. E. Humphries, et al. Genetic Variants of Angiotensin II Receptors and Cardiovascular Risk in Hypertension Hypertension, October 1, 2003; 42(4): 500 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Cohn, I. S. Anand, R. Latini, S. Masson, Y.-T. Chiang, and R. Glazer Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial Circulation, September 16, 2003; 108(11): 1306 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Sasso, O. Carbonara, M. Persico, D. Iafusco, T. Salvatore, R. D'Ambrosio, R. Torella, and D. Cozzolino Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension: A randomized double-blind placebo-controlled crossover study Diabetes Care, November 1, 2002; 25(11): 1909 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Soler-Soler and D. Garcia-Dorado How to best to counteract the enemies? By blocking neurohormonal activation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G45 - G50. [Abstract] [PDF]
|
|
|
|
|
|
M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]
|
|
|
|
|
|
C. Berry Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy Eur. Heart J., September 1, 2000; 21(17): 1484 - 1485. [PDF]
|
|
|
|
|
|
C. Berry Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy Eur. Heart J., September 1, 2000; 21(17): 1484 - 1485. [PDF]
|
|
|
|
|
|
S. Hanon, P. Vijayaraman, E. H Sonnenblick, and T. H Le Jemtel Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 147 - 150. [PDF]
|
|